WO1999022002A1 - Nouveau cycline mitogene et son utilisation - Google Patents

Nouveau cycline mitogene et son utilisation Download PDF

Info

Publication number
WO1999022002A1
WO1999022002A1 PCT/EP1998/006749 EP9806749W WO9922002A1 WO 1999022002 A1 WO1999022002 A1 WO 1999022002A1 EP 9806749 W EP9806749 W EP 9806749W WO 9922002 A1 WO9922002 A1 WO 9922002A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant
cell
protein
mitogenic
dna sequence
Prior art date
Application number
PCT/EP1998/006749
Other languages
English (en)
Inventor
Dirk INZÉ
Lieven De Veylder
Janice De Almeide
Original Assignee
Cropdesign N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cropdesign N.V. filed Critical Cropdesign N.V.
Priority to JP2000518093A priority Critical patent/JP2001520887A/ja
Priority to AU15572/99A priority patent/AU754851B2/en
Priority to CA002307171A priority patent/CA2307171A1/fr
Priority to EP98959796A priority patent/EP1025232A1/fr
Publication of WO1999022002A1 publication Critical patent/WO1999022002A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/08—Magnoliopsida [dicotyledons]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Definitions

  • the present invention relates to DNA sequences encoding mitogenic cyclins as well as to methods for obtaining the same.
  • the present invention also provides vectors comprising said DNA sequences, wherein the DNA sequences are operatively linked to regulatory elements allowing expression in prokaryotic and/or eukaryotic host cells.
  • the present invention relates to the proteins encoded by said DNA sequences, antibodies to said proteins and methods for their production.
  • the present invention also relates to a method for controlling or altering growth characteristics of a plant and/or a plant cell comprising introduction and/or expression of one or more mitogenic cyclins functional in a plant or parts thereof and/or one or more DNA sequences encoding such proteins.
  • the present invention further relates to diagnostic compositions comprising the aforementioned DNA sequences, proteins and antibodies.
  • the present invention also relates to methods for the identification of compounds being capable of activating or inhibiting the cell cycle.
  • the present invention relates to transgenic plant cells, plant tissue and plants containing the above-described DNA sequences and vectors as well as to the use of the aforementioned DNA sequences, vectors, proteins, antibodies and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding and/or agriculture.
  • CDK cyclin-dependent protein kinase
  • pombe and in S. cerevisiae, respectively, is dependent on the regulatory proteins, so-called cyclins as mentioned above. Progression through the different cell cycle phases is achieved by the sequential association of p34 cd 2 cdc28 vvith different cyclins. Although in higher eukaryotes this regulation mechanism is conserved, the situation is more complex since they have evolved to use multiple CDKs to regulate the different stages of the cell cycle. In mammals, seven CDKs have been described defined as CDK1 to CDK7, each binding a specific subset of cyclins.
  • the activity of cdk/cyclin complexes is regulated at five levels: (i) transcription of the CDK and cyciin genes; (ii) association of specific CDKs with their specific cyciin partner; (iii) phosphorylation/ dephosphorylation of the CDK and cyciin subunits; (iv) interaction with other regulatory proteins such as SUC1/CKS1 homologues and cell cycle kinase inhibitors (CKI); and (v) cell cycle phase-dependent destruction of the cyclins.
  • CDKs are distinguished by several features. First, only CDC2aAt is able to complement yeast p 34 cdc2 cdc28 mutants. Second, CDC2aAt and CDC2bAt bear different cyciin- binding motifs (PSTAIRE and PPTALRE, respectively), suggesting they may bind distinct types of cyclins. Third, although both CDC2aAt and CDC2bAt show the same spatial expression pattern, they exhibit a different cell cycle phase-specific regulation. The CDC2aAt gene is expressed constitutively throughout the whole cell cycle. In contrast, CDC2bAt mRNA levels oscillate, being most abundant during the S and G 2 phases.
  • D-type cyclins are only distantly related to other cyclins. In mammals D-type cyclins act as growth sensors, with their expression depending more on extracellular cues than on the cell's position in the cell cycle. Consequently D-type cyclins has been suggested to mediate mitogenic stimuli with the release from quiescence. This is believed to be regulated through the hyperphosphorylation of the retinoblastoma protein (Rb) by CDK/cyclin D complexes.
  • Rb retinoblastoma protein
  • Rb is a tumour suppressor protein which plays an important role in controlling the onset of cell division.
  • Rb is complexed with E2F-type transcription factors which are known to promote expression of S phase-specific genes. Binding of Rb to E2Fs thereby prevents S phase induction.
  • Phosphorylated Rb is unable to form complexes with E2F transcription factors and allows DNA synthesis. All D-type cyclins show a specific amino acid motif (LXCXE) permitting them to bind Rb.
  • CYCD1;1 is most abundant in flowers and leaves, CYCD2;1 in leaves and roots, and CYCD3;1 in roots.
  • the CYCD2;1 transcript level remains unchanged during the whole cell cycle (Fuerst, Plant Physiol. 112 (1996), 1023-1033). Therefore, the A. thaliana D-type cyciin genes are expressed in a cell cycle phase- independent manner, just as described for their mammalian counterparts. Rather, transcription is regulated by the presence of mitogens. In starved cell cultures, CYCD2;1 expression is inducible by the addition of sucrose only, whereas CYCD3;1 transcription is inducible by cytokinins (Soni, Plant Cell 7 (1995), 85-103). The observation that distinct D-type cyclins respond to different mitogenic stimuli suggests that each of them is involved in particular signal transduction pathways linking the perception of mitogenic stimuli with the cell cycle.
  • the technical problem underlying the present invention is to provide means and methods for modulating cell cycle proteins that are particular useful in agriculture and plant cell and tissue culture.
  • the invention relates to a DNA sequence encoding a mitogenic cyciin or encoding an immunologically active and/or functional fragment of such a protein, selected from the group consisting of:
  • mitogenic refers to compounds (chemicals or proteins) which positively influence reentry into the cell cycle and/or progression of the cell cycle; see also Example 4.
  • Cyciin means one of the proteins which actively regulate cell division.
  • cell cycle means the cyclic biochemical and structural events associated, with growth of cells, and in particular with the regulation of the replication of DNA and mitosis.
  • the cycle is divided into periods called: G 0 , Gap-, (G , DNA synthesis (S), Gap 2 (G 2 ), and mitosis (M).
  • proliferation means growth and reproduction, i.e. division of cells.
  • cell division means mitosis, i.e. the usual process of cell reproduction.
  • nucleic acid molecule(s) refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA, and RNA. It also includes known types of modifications, for example, methylation, "caps" substitution of one or more of the naturally occuring nucleotides with an analog.
  • the DNA sequence of the invention comprises a coding sequence encoding the above defined mitogenic cyciin.
  • a “coding sequence” is a nucleotide sequence which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'- terminus.
  • a coding sequence can include, but is not limited to mRNA, cDNA, recombinant nucleotide sequences or genomic DNA, while introns may be present as well under certain circumstances.
  • CDC2aAt as bait and a cDNA library of a cell suspension as prey are used.
  • the library was made from a mixture mRNA from Arabidopsis thaliana cell suspensions harvested at various growing stages: early exponential, exponential, early stationary and stationary phase. A positive clone was identified. The clone was first designated as LDV 59 and encodes a novel mitogenic cyciin. According to the nomenclature in Renaudin et al., Plant Mol. Biol. 32 (1996), 1003-1018, the novel mitogenic gene of the invention is also referred to herein as CYCD4;1, a novel class of D-type cyclins.
  • the CYCD4;1 gene contains a 5' untranslated region of 117 bp. Because CYCD4;1 was isolated as a fusion protein with the GAL4 activation domain, no upstream in- W
  • initiation codon at position 118 contains a good consensus translation start sequence (GxxAUGG; Kozak 1987, J. Mol. Biol. 196, p947-950).
  • GxxAUGG Kozak 1987, J. Mol. Biol. 196, p947-950.
  • CYCD4 " /-encoded protein of 308 amino acids (SEQ ID NO: 2) has a calculated molecular mass of approximately 34 kDa and bears an Rb-interaction motif in its amino terminus (amino acids 10 to 14).
  • the CYCD4;1 protein only shows significant sequence similarity to the other A. thaliana D-type cyclins within its amino-terminal domain, especially the cyciin box
  • CYCD4;1 exhibits 37.2%, 44.4%, and 31.9% identity with CYCD1 ;1 , CYCD2;1 , and CYCD3;1 , respectively (Table 1 ).
  • the CYCD4;1 protein is most closely related to CYCD2;1 , although their sequence similarity is limited to 52.3% (Table 1 ).
  • the carboxyl-terminal domain of CYCD4;1 is also significantly shorter than that of CYCD2;1 , resulting in a remarkable difference in protein size (34 kDa and 43 kDa for CYCD4;1 and CYCD2;1 , respectively), and consequently in the putative protein structure. Therefore, CYCD2;1 and CYCD4;1 can be considered as members of different groups.
  • the gene comprising the nucleotide sequence of SEQ ID NO.1 encodes a member of a novel class of mitogenic cyclins.
  • the present invention also relates to DNA sequences hybridizing with the above- described DNA sequences and differ in one or more positions in comparison with these as long as they encode a mitogenic cyciin.
  • hybridizing it is meant that such nucleic acid molecules hybridize under conventional hybridization conditions, preferably under stringent conditions such as described by, e.g., Sambrook (Molecular Cloning; A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)).
  • stringent hybridization condition is hybridization at 4XSSC at 65 °C, followed by a washing in 0.1XSSC at 65 °C for one hour.
  • an exemplary stringent hybridization condition is in 50 % formamide, 4XSSC at 42 °C.
  • Mitogenic cyclins derived from other organisms such as mammals, in particular humans, may be encoded by other DNA sequences which hybridize to the sequences for plant mitogenic cyclins under relaxed hybridization conditions and which code on expression for peptides having the ability to interact with cell cycle proteins.
  • Examples of such non-stringent hybridization conditions are 4XSSC at 50 °C or hybridization with 30-40 % formamide at 42 °C.
  • Such moiecules comprise those which are fragments, analogues or derivatives of the mitogenic cyciin of the invention and differ, for example, by way of amino acid and/or nucleotide deletion(s), insertion(s), substitution(s), addition(s) and/or recombination(s) or any other modification(s) known in the art either alone or in combination from the above- described amino acid sequences or their underlying nucleotide sequence(s). Methods for introducing such modifications in the nucleic acid molecules according to the invention are well-known to the person skilled in the art.
  • the invention also relates to nucleic acid molecules the sequence of which differs from the nucleotide sequence of any of the above-described nucleic acid molecules due to the degeneracy of the genetic code. All such fragments, analogues and derivatives of the protein of the invention are included within the scope of the present invention, as long as the essential characteristic immunological and/or biological properties as defined above remain unaffected in kind, that is the novel nucleic acid molecules of the invention include all nucleotide sequences encoding proteins or peptides which have at least a part of the primary structural conformation for one or more epitopes capable of reacting with antibodies to mitogenic cyclins which are encodable by a nucleic acid molecule as set forth above and which have comparable or identical characteristics in terms of biological activity and/or the capability to interact with other proteins.
  • Part of the invention is therefore aiso nucleic acid molecules encoding a polypeptide comprising at least a functional part of a mitogenic cyciin encoded by a nucleic acid sequence comprised in a nucleic acid molecule according to the invention.
  • a polypeptide comprising at least a functional part of a mitogenic cyciin encoded by a nucleic acid sequence comprised in a nucleic acid molecule according to the invention.
  • the polypeptide or a fragment thereof according to the invention is embedded in another amino acid sequence.
  • the DNA sequence of the invention encodes a protein having substantially the same amino acid sequence as the protein defined in SEQ ID NO 2.
  • the present invention relates to a method for identifying and obtaining mitogenic cyclins comprising a two-hybrid screening assay wherein CDC2a as a bait and a cDNA library of cell suspension culture as prey are used.
  • CDC2a is CDC2aAt.
  • PEST containing CDKs from other plants and/or other organisms such as mammals may be employed as well.
  • the cell culture may be from any organism possessing mitogenic cyclins such as animals, preferably mammals. Particularly preferred are plant cell suspension cultures such as from Arabidopsis.
  • nucleic acid molecules encoding proteins or peptides identified to interact with the CDC2a in the above mentioned assay can be easily obtained and sequenced by methods known in the art; see also the appended examples. Therefore, the present invention also relates to a DNA sequence encoding a mitogenic cyciin obtainable by the method of the invention.
  • the nucleic acid molecules according to the invention are RNA or DNA molecules, preferably cDNA, genomic DNA or synthetically synthesized DNA or RNA molecules.
  • the nucleic acid molecule of the invention is derived from a plant, preferably from Arabidopsis thaliana.
  • Nucleic acid molecules of the invention can be obtained, e.g., by hybridization of the above-described nucleic acid molecules with a (sample of) nucleic acid molecule(s) of any source.
  • Nucleic acid molecules hybridizing with the above-described nucleic acid molecules can in general be derived from any organism, preferably plants possessing such molecules, preferably from monocotyledonous or dicotyledonous plants, in particular from plants of interest in agriculture, horticulture or wood culture, such as crop plants, namely those of the family Poaceae, any starch producing plants, such as potato, maniok, leguminous plants, oil producing plants, such as oilseed rape, linenseed, etc., plants using polypeptide as storage substances, such as soybean, plants using sucrose as storage substance, such as sugar beet or sugar cane, trees, ornamental plants etc.
  • the nucleic acid molecules according to the invention are derived from Arabidopsis thaliana.
  • Nucleic acid molecules hybridizing to the above-described nucleic acid molecules can be isolated, e.g., form libraries, such as cDNA or genomic libraries by techniques well known in the art. For example, hybridizing nucleic acid molecules can be identified and isolated by using the above-described nucleic acid molecules or fragments thereof or complements thereof as probes to screen libraries by hybridizing with said molecules according to standard techniques. Possible is also the isolation of such nucleic acid molecules by applying a nucleic acid amplicification technique such as the polymerase chain reaction (PCR) using as primers oligonucleotides derived form the above-described nucleic acid molecules.
  • PCR polymerase chain reaction
  • Nucleic acid molecules which hybridize with any of the aforementioned nucleic acid molecules also include fragments, derivatives and allelic variants of the above- described nucleic acid molecules that encode a mitogenic cyciin or an immunologically or functional fragment thereof. Fragments are understood to be parts of nucleic acid molecules long enough to encode the described protein or a functional or immunologically active fragment thereof as defined above.
  • the functional fragment contains at least the cyciin box of the CYCD4 protein shown in Figure 1.
  • the fragment comprises amino acid residues 78 to 182 of the amino acid sequence of SEQ ID NO:2.
  • nucleotide sequence of these nucleic acid molecules differs from the sequences of the above-described nucleic acid molecules in one or more nucleotide positions and are highly homologous to said nucleic acid molecules.
  • Homology is understood to refer to a sequence identity of at least 40 %, particularly an identity of at least 60 %, preferably more than 80 % and still more preferably more than 90 %.
  • substantially homologous refers to a subject, for instance a nucleic acid, which is at least 50% identical in sequence to the reference when the entire ORF (open reading frame) is compared, where the sequence identity is preferably at least 70%, more preferably at least
  • nucleic acid molecules described above can, for example, be the result of nucleotide substitution(s), deletion(s), addition(s), insertion(s) and/or recombination(s); see supra.
  • nucleic acid molecules or encoded proteins are functionally and/or structurally equivalent.
  • the nucleic acid molecules that are homologous to the nucleic acid molecules described above and that are derivatives of said nucleic acid molecules are, for example, variations of said nucleic acid molecules which represent modifications having the same biological function, in particular encoding proteins with the same or substantially the same biological function. They may be naturally occurring variations, such as sequences from other plant varieties or species, or mutations. These mutations may occur naturally or may be obtained by mutagenesis techniques.
  • allelic variations may be naturally occurring allelic variants as well as synthetically produced or genetically engineered variants; see supra.
  • the proteins encoded by the various derivatives and variants of the above- described nucleic acid molecules may share specific common characteristics, such as biological activity, molecular weight, immunological reactivity, conformation, etc., as well as physical properties, such as electrophoretic mobility, chromatographic behavior, sedimentation coefficients, pH optimum, temperature optimum, stability, solubility, spectroscopic properties, etc.
  • the invention relates to nucleic acid molecules of at least 15 nucleotides in length hybridizing specifically with a nucleic acid molecule as described above or with a complementary strand thereof. Specific hybridization occurs preferably under stringent conditions and implies no or very little cross- hybridization with nucleotide sequences encoding no or substantially different proteins.
  • nucleic acid molecules may be used as probes and/or for the control of gene expression.
  • Nucleic acid probe technology is well known to those skilled in the art who will readily appreciate that such probes may vary in length. Preferred are nucleic acid probes of 16 to 35 nucleotides in length. Of course, it may also be appropriate to use nucleic acids of up to 100 and more nucleotides in length.
  • nucleic acid probes of the invention are useful for various applications. On the one hand, they may be used as PCR primers for amplification of nucleic acid sequences according to the invention.
  • the design and use of said primers is known by the person skilled in the art.
  • amplification primers comprise a contiguous sequence of at least 6 nucleotides, in particular 13 nucleotides, preferably 15 to 25 nucleotides or more, identical or complementary to the nucleotide sequence depicted in SEQ ID NO: 1 or to a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2.
  • nucleic acid molecules according to this preferred embodiment of the invention which are complementary to a nucleic acid molecule as described above may also be used for repression of expression of a cell cycle gene, for example due to an antisense or triple helix effect or for the construction of appropriate ribozymes (see, e.g., EP-A1 0 291 533, EP-A1 0 321 201 , EP-A2 0 360 257) which specifically cleave the (pre)-mRNA of a gene comprising a nucleic acid molecule of the invention or part thereof.
  • nucleic acid molecules may either be DNA or RNA or a hybrid thereof.
  • said nucleic acid molecule may contain, for example, thioester bonds and/or nucleotide analogues, commonly used in oligonucleotide anti-sense approaches. Said modifications may be useful for the stabilization of the nucleic acid molecule against endo- and/or exonucleases in the cell.
  • Said nucleic acid molecules may be transcribed by an appropriate vector containing a chimeric gene which allows for the transcription of said nucleic acid molecule in the cell.
  • PNA peptide nucleic acid
  • the so-called "peptide nucleic acid” (PNA) technique can be used for the detection or inhibition of the expression of a nucleic acid molecule of the invention.
  • PNA peptide nucleic acid
  • the binding of PNAs to complementary as well as various single stranded RNA and DNA nucleic acid molecules can be systematically investigated using thermal denaturation and BIAcore surface-interaction techniques (Jensen, Biochemistry 36 (1997), 5072-5077).
  • the nucleic acid molecules described above as well as PNAs derived therefrom can be used for detecting point mutations by hybridization with nucleic acids obtained from a sample, with an affinity sensor, such as BIAcore; see Gotoh, Rinsho Byori 45 (1997), 224- 228.
  • PNA peptide nucleic acids
  • PNAs for example as restriction enzymes or as templates for the synthesis of nucleic acid oligonucleotides are known to the person skilled in the art and are, for example, described in Veselkov, Nature 379 (1996), 214 and Bohler,
  • the present invention also relates to vectors, particularly plasmids, cosmids, viruses, bacteriophages and other vectors used conventionally in genetic engineering that contain a nucleic acid molecule according to the invention.
  • vectors particularly plasmids, cosmids, viruses, bacteriophages and other vectors used conventionally in genetic engineering that contain a nucleic acid molecule according to the invention.
  • Methods which are well known to those skilled in the art can be used to construct various plasmids and vectors; see, for example, the techniques described in Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1989).
  • the nucleic acid molecules and vectors of the invention can be reconstituted into liposomes for delivery to target cells.
  • nucleic acid molecule present in the vector is linked to (a) control sequence(s) which allow the expression of the nucleic acid molecule in prokaryotic and/or eukaryotic cells.
  • control sequence refers to regulatory DNA sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism. In prokaryotes, control sequences generally include promoter, ribosomal binding site, and terminators. In eukaryotes generally control sequences include promoters, terminators and, in some instances, enhancers, transactivators or transcription factors.
  • control sequence is intended to include, at a minimum, al! components the presence of which are necessary for expression, and may also include additional advantageous components.
  • operably linked refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
  • control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
  • control sequence is a promoter, it is obvious for a skilled person that double-stranded nucleic acid is used.
  • the vector of the invention is preferably an expression vector.
  • An "expression vector” is a construct that can be used to transform a selected host cell and provides for expression of a coding sequence in the selected host.
  • Expression vectors can for instance be cloning vectors, binary vectors or integrating vectors.
  • Expression comprises transcription of the nucleic acid molecule preferably into a translatable mRNA.
  • Regulatory elements ensuring expression in prokaryotic and/or eukaryotic cells are well known to those skilled in the art.
  • eukaryotic cells they comprise normally promoters ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript, for example, those of the 35S RNA from Cauliflower Mosaic Virus (CaMV).
  • Other promoters commonly used are the polyubiquitin promoter, and the actin promoter for ubiquitous expression.
  • the termination signals usually employed are from the
  • Nopaline Synthase promoter or from the CAMV 35S promoter is the TMV omega sequences, the inclusion of an intron
  • Additional regulatory elements may include transcriptional as well as translational enhancers.
  • Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the P L , lac, trp or tac promoter in E. coli, and examples of regulatory elements permitting expression in eukaryotic host cells are the AOX1 or GAL1 promoter in yeast or the
  • CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells.
  • suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc/CMV, pcDNAI , pcDNA3 (In-vitrogene), pSPORTI (GIBCO BRL).
  • the above-described vectors of the invention comprises a selectable and/or scorable marker.
  • Selectable marker genes useful for the selection of transformed plant cells, callus, plant tissue and plants are well known to those skilled in the art and comprise, for example, antimetabolite resistance as the basis of selection for dhfr, which confers resistance to methotrexate (Reiss, Plant Physiol. (Life Sci. Adv.) 13 (1994), 143-149); npt, which confers resistance to the aminoglycosides neomycin, kanamycin and paromycin
  • trpB which allows cells to utilize indole in place of tryptophan
  • hisD which allows cells to utilize histinol in place of histidine
  • mannose-6-phosphate isomerase which allows cells to utilize mannose
  • ODC omithine decarboxylase
  • Useful scorable marker are also known to those skilled in the art and are commercially available.
  • said marker is a gene encoding luciferase
  • the present invention furthermore relates to host cells comprising a vector as described above or a nucleic acid molecule according to the invention wherein the nucleic acid molecule is foreign to the host cell.
  • nucleic acid molecule is either heteroiogous with ⁇ respect to the host cell, this means derived from a cell or organism with a different genomic background, or is homologous with respect to the host cell but located in a different genomic environment than the naturally occurring counterpart of said nucleic acid molecule. This means that, if the nucleic acid molecule is homologous with respect to the host cell, it is not located in its natural location in the genome of said host cell, in particular it is surrounded by different genes. In this case the nucleic acid molecule may be either under the control of its own promoter or under the control of a heterologous promoter.
  • the vector or nucleic acid molecule according to the invention which is present in the host cell may either be integrated into the genome of the host cell or it may be maintained in some form extrachromosomally.
  • the nucleic acid molecule of the invention can be used to restore or create a mutant gene via homologous recombination (Paszkowski (ed.), Homologous Recombination and Gene Silencing in Plants. Kluwer Academic Publishers (1994)).
  • the host cell can be any prokaryotic or eukaryotic cell, such as bacterial, insect, fungal, plant or animal cells.
  • Preferred fungal cells are, for example, those of the genus Saccharomyces, in particular those of the species S. cerevisiae.
  • Another subject of the invention is a method for the preparation of mitogenic cyclins which comprises the cultivation of host cells according to the invention which, due to the presence of a vector or a nucleic acid molecule according to the invention, are able to express such a protein, under conditions which allow expression of the protein and recovering of the so-produced protein from the culture.
  • expression means the production of a protein or nucleotide sequence in the cell. However, said term also includes expression of the protein in a cell-free system. It includes transcription into an RNA product, post-transcriptional modification and/or translation to a protein product or polypeptide from a DNA encoding that product, as well as possible post-translational modifications.
  • the protein may be recovered from the cells, from the culture medium or from both.
  • the protein it is well known that it is not only possible to express a native protein, but also to express the protein as fusion polypeptides or to add signal sequences directing the protein to specific compartments of the host cell, e.g., ensuring secretion of the protein into the culture medium, etc.
  • a protein and fragments thereof can be chemically synthesized and/or modified according to standard methods described, for example hereinbelow.
  • protein and “polypeptide” used in this application are interchangeable.
  • Polypeptide refers to a polymer of amino acids (amino acid sequence) and does not refer to a specific length of the molecule. Thus peptides and oligopeptides are included within the definition of polypeptide. This term does also refer to or include post-translational modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non- naturally occurring.
  • the present invention furthermore relates to proteins encoded by the nucleic acid molecules according to the invention or produced or obtained by the above- described methods, and to functional and/or immunologically active fragments of such mitogenic cyclins.
  • the proteins and polypeptides of the present invention are not necessarily translated from a designated nucleic acid sequence; the polypeptides may be generated in any manner, including for example, chemical synthesis, or expression of a recombinant expression system, or isolation from a suitable viral system.
  • the polypeptides may include one or more analogs of amino acids, phosphorylated amino acids or unnatural amino acids. Methods of inserting analogs of amino acids into a sequence are known in the art.
  • the polypeptides may also include one or more labels, which are known to those skilled in the art.
  • proteins according to the invention may be further modified by conventional methods known in the art.
  • the proteins according to the present invention it is also possible to determine fragments which retain biological activity. This allows the construction of chimeric proteins and peptides comprising an amino sequence derived from the protein of the invention;, which is crucial for its, e.g., binding activity and other functional amino acid sequences, e.g. GUS marker gene (Jefferson, EMBO J. 6 (1987), 3901-3907).
  • the other functional amino acid sequences may be either physically linked by, e.g., chemical means to the proteins of the invention or may be fused by recombinant
  • fragment of a sequence or "part of a sequence” means a truncated sequence of the original sequence referred to.
  • the truncated sequence can vary widely in length; the minimum size being a sequence of sufficient size to provide a sequence with at least a comparable function and/or activity of the original sequence referred to, while the maximum size is not critical. In some applications, the maximum size usually is not substantially greater than that required to provide the desired activity and/or function(s) of the original sequence.
  • the truncated amino acid sequence will range from about 5 to about 60 amino acids in length. More typically, however, the sequence will be a maximum of about 50 amino acids in length, preferably a maximum of about 30 amino acids. It is usually desirable to select sequences of at least about 10, 12 or 15 amino acids, up to a maximum of about 20 or 25 amino acids.
  • folding simulations and computer redesign of structural motifs of the protein of the invention can be performed using appropriate computer programs
  • incorporation of easily available achiral ⁇ -amino acid residues into a protein of the invention or a fragment thereof results in the substitution of amide bonds by polymethylene units of an aliphatic chain, thereby providing a convenient strategy for constructing a peptidomimetic (Banerjee, Biopolymers 39 (1996), 769-777).
  • peptidomimetic combinatorial libraries can also be identified by the synthesis of peptidomimetic combinatorial libraries through successive amide alkylation and testing the resulting compounds, e.g., for their binding and immunological properties. Methods for the generation and use of peptidomimetic combinatorial libraries are described in the prior art, for example in
  • a three-dimensional and/or crystallographic structure of the protein of the invention can be used for the design of peptidomimetic inhibitors of the biological activity of the protein of the invention (Rose, Biochemistry 35 (1996), 12933-12944;
  • the present invention relates to antibodies specifically recognizing a mitogenic cyciin according to the invention or parts, i.e. specific fragments or epitopes, of such a protein.
  • the antibodies of the invention can be used to identify and isolate other mitogenic cyclins and genes in any organism, preferably plants.
  • These antibodies can be monoclonal antibodies, polyclonal antibodies or synthetic antibodies as well as fragments of antibodies, such as Fab, Fv or scFv fragments etc.
  • Monoclonal antibodies can be prepared, for example, by the techniques as originally described in K ⁇ hler and Milstein, Nature 256 (1975), 495, and Galfre, Meth. Enzymol.
  • antibodies or fragments thereof to the aforementioned peptides can be obtained by using methods which are described, e.g., in Harlow and Lane “Antibodies, A Laboratory Manual", CSH Press,, Cold Spring Harbor, 1988. These antibodies can be used, for example, for the immunoprecipitation and immunolocalization of proteins according to the invention as well as for the monitoring of the synthesis of such proteins, for example, in recombinant organisms, and for the identification of compounds interacting with the protein according to the invention.
  • surface plasmon resonance as employed in the BIAcore system can be used to increase the efficiency of phage antibodies selections, yielding a high increment of affinity from a single library of phage antibodies which bind to an epitope of the protein of the invention (Schier,
  • Plant cell division can conceptually be influenced in three ways : (i) inhibiting or arresting cell division, (ii) maintaining, facilitating or stimulating cell division or (iii) uncoupling DNA synthesis from mitosis and cytokinesis.
  • Modulation of the expression of a mitogenic cyciin encoded by a nucleotide sequence according to the invention has surprisingly an advantageous influence on plant cell division characteristics, in particular on the disruption of the expression levels of genes involved in G1/S and/or G2/M transition and as a result therof on the total make-up of the plant concerned or parts thereof.
  • An example is that DNA synthesis or progression of DNA replication will be negatively influenced by interfering with the formation of a cyclin-dependent protein kinase complex.
  • cyclin-dependent protein kinase complex means the complex formed when a, preferably functional, cyciin associates with a, preferably, functional cyciin dependent kinase. Such complexes may be active in phosphorylating proteins and may or may not contain additional protein species.
  • protein kinase means an enzyme catalyzing the phosphorylation of proteins.
  • transformed plants can be made overproducing the nucleotide sequence according to the invention.
  • Such an ⁇ overexpression of the new gene(s), proteins or inactivated variants thereof will either positively or negatively have an effect on cell division.
  • Methods to modify the expression levels and/or the activity are known to persons skilled in the art and include for instance overexpression, co-suppression, the use of ribozymes, sense and anti-sense strategies, gene silencing approaches.
  • Sense strand refers to the strand of a double-stranded DNA molecule that is homologous to a mRNA transcript thereof.
  • the "anti-sense strand” contains an inverted sequence which is complementary to that of the "sense strand”.
  • the nucleic acid molecules according to the invention are in particular useful for the genetic manipulation of plant cells in order to modify the characteristics of plants and to obtain plants with modified, preferably with improved or useful phenotypes.
  • the invention can also be used to modulate the cell division and the growth of cells, preferentially plant cells, in in vitro cultures.
  • the plant cell division rate and/or the inhibition of a plant cell division can be influenced by overexpression or reducing the expression of a gene encoding a protein according to the invention.
  • Overexpression of a cyciin gene according to the invention promotes cell proliferation, while reducing cyciin expression arrests cell division or prevents reentry into the cell cycle.
  • Part of the invention is thus the usage of a cyciin comprising the coding sequence or part thereof as mentioned hereinbefore as a negative or positive regulator of cell proliferation.
  • a transformed plant can thus be obtained by transforming a plant cell with a gene encoding a polypeptide concerned or fragment thereof alone or in combination, whereas the plant cell may belong to a monocotyledonous or dicotyledonous plant.
  • tissue specific promoters in one construct or being present as a separate construct in addition to the sequence concerned, can be used.
  • the expression of the cyciin is inducible by cytokinines or sucrose.
  • cell division of the meristems of the plant can be manipulated, positively and/or negatively respectively.
  • overproduction of the cyciin enhances growth A and results in cell division to be less sensitive to an arrest caused by environmental stress such as salt, drought, chilling and the like.
  • the present invention provides a method for the production of transgenic plants, plant cells or plant tissue comprising the introduction of a nucleic acid molecule or vector of the invention into the genome of said plant, plant cell or plant tissue.
  • the molecules are placed under the control of regulatory elements which ensure the expression in plant cells.
  • regulatory elements may be heterologous or homologous with respect to the nucleic acid molecule to be expressed as well with respect to the plant species to be transformed.
  • regulatory elements comprise a promoter active in plant cells.
  • constitutive promoters such as the 35 S promoter of CaMV (Odell, Nature 313 (1985), 810-812) or promoters of the polyubiquitin genes of maize (Christensen, Plant Mol. Biol. 18 (1982), 675-689).
  • tissue specific promoters see, e.g., Stockhaus, EMBO J. 8 (1989), 2245-2251 ).
  • tissue specific promoters which are specifically active in tubers of potatoes or in seeds of different plants species, such as maize, Vicia, wheat, barley etc.
  • Inducible promoters may be used in order to be able to exactly control expression.
  • An example for inducible promoters are the promoters of genes encoding heat shock proteins.
  • microspore-specific regulatory elements and their uses have been described (WO96/16182).
  • the chemically inducible Tet-system may be employed (Gate, Mol. Gen. Genet. 227 (1991); 229-237).
  • the regulatory elements may further comprise transcriptional and/or translational enhancers functional in plants cells.
  • the regulatory elements may include transcription termination signals, such as a poly- A signal, which lead to the addition of a poly A tail to the transcript which may improve its stability.
  • transcription termination signals such as a poly- A signal
  • Methods for the introduction of foreign DNA into plants are also well known in the art. These include, for example, the transformation of plant cells or tissues with T-DNA using Agrobacterium tumefaciens or Agrobacterium rhizogenes, the fusion of protoplasts, direct gene transfer (see, e.g., EP-A 164 575), injection, electroporation, biolistic methods like particle bombardment, pollen-mediated transformation, plant RNA virus-mediated transformation, liposome-mediated transformation, transformation using wounded or enzyme-degraded immature embryos, or wounded or enzyme-degraded embryogenic callus and other methods known in the art.
  • the vectors used in the method of the invention may contain further functional elements, for example "left border”- and “right border”-sequences of the T-DNA of Agrobacterium which allow for stably integration into the plant genome.
  • methods and vectors are known to the person skilled in the art which permit the generation of marker free transgenic plants, i.e. the selectable or scorable marker gene is lost at a certain stage of plant development or plant breeding. This can be achieved by, for example cotransformation (Lyznik, Plant Mol. Biol. 13 (1989), 151- 161 ; Peng, Plant Mol. Biol.
  • Suitable strains of Agrobacterium tumefaciens and vectors as well as transformation of Agrobacteria and appropriate growth and selection media are well known to those skilled in the art and are described in the prior art (GV3101 (pMK90RK), Koncz, Mol.
  • Agrobacterium tumefaciens Although the use of Agrobacterium tumefaciens is preferred in the method of the invention, other Agrobacterium strains, such as Agrobacterium rhizogenes, may be used, for example if a phenotype conferred by said strain is desired.
  • Microinjection can be performed as described in Potrykus and
  • transformation refers to the transfer of an exogenous polynucleotide into a host cell, irrespective of the method used for the transfer.
  • the ; , polynucleotide may be transiently or stably introduced into the host cell and may be maintained non-integrated, for example, as a plasmid or as chimeric links, or alternatively, may be integrated into the host genome.
  • the resulting transformed plant cell can then be used to regenerate a transformed plant in a manner known by a skilled person.
  • the plants which can be modified according to the invention and which either show overexpression of a protein according to the invention or a reduction of the synthesis of such a protein can be derived from any desired plant species.
  • They can be monocotyledonous plants or dicotyledonous plants, preferably they belong to plant species of interest in agriculture, wood culture or horticulture interest, such as crop plants (e.g. maize, rice, barley, wheat, rye, oats etc.), potatoes, oil producing plants (e.g. oilseed rape, sunflower, pea nut, soy bean, etc.), cotton, sugar beet, sugar cane, leguminous plants (e.g. beans, peas etc.), wood producing plants, preferably trees, etc.
  • crop plants e.g. maize, rice, barley, wheat, rye, oats etc.
  • potatoes oil producing plants
  • oil producing plants e.g. oilseed rape, sunflower, pea nut, soy bean, etc.
  • the present invention relates also to transgenic plant cells which contain (preferably stably integrated into the genome) a nucleic acid molecule according to the invention linked to regulatory elements which allow expression of the nucleic acid molecule in plant cells and wherein the nucleic acid molecule is foreign to the transgenic plant cell.
  • a nucleic acid molecule according to the invention linked to regulatory elements which allow expression of the nucleic acid molecule in plant cells and wherein the nucleic acid molecule is foreign to the transgenic plant cell.
  • the presence and expression of the nucleic acid molecule in the transgenic plant cells leads to the synthesis of a mitogenic cyciin and leads to physiological and phenotypic changes in plants containing such cells.
  • the present invention also relates to transgenic plants and plant tissue comprising transgenic plant cells according to the invention. Due to the (over)expression of a mitogenic cyciin of the invention, e.g., at developmental stages and/or in plant tissue in which they do not naturally occur these transgenic plants may show various physiological, developmental and/or morphological modifications in comparison to wild-type plants.
  • a thaliana CYCD4;1 gene its coding region can be cloned, e.g., into the pAT7002 vector (Aoyama and Chua, 997, Plant J. 11 , p605-612).
  • This vector allows inducible expression of the cloned inserts by the addition of the glucocorticoid dexamethasone.
  • PCR polymerase chain reaction
  • CYCD4;1 can be amplified using 5'-GAACACTCGAGTGTAATGGCAGAGG-3' (SEQ ID NO: 1
  • the obtained PCR fragment can be purified and cut with Xhol and Spel.
  • the fragment can be cloned into the Xhol and Spel sites of pTA7002.
  • the resulted binary vector can be transferred into Agrobacterium tumefaciens.
  • This strain can be used to transform Nicotiana tabacum cv. Petit havana using, e.g., the leaf disk protocol (Horsh et al., 1985, Science 227, ⁇ 1229-1231 ) and Arabidopsis thaliana using, e.g., the root transformation protocol (Valvekens et al., 1988, PNAS
  • Transgenic plants can then be selected on hygromycine 20 mg/l.
  • Plants can be tested for CYCD4 inducible expression as follows. 2 to 3 leaves of each transformant can be cut in two. Each half can be either submersed in 50 mM Na-citrate buffer (pH 5.8) with or without dexamethasone (0.03 mM concentration). After 24 hours of induction RNA can be extracted from these leaves using the Trizol reagents (Gibco-BRL) according to the manufactures and a northern gel can be run using, e.g., 5 ⁇ g of RNA. The gel can be blotted on a nitro-cellulose filter (HybondN+, Amersham) and hybridised with a CYCD4 probe.
  • Trizol reagents Gibco-BRL
  • a northern gel can be run using, e.g., 5 ⁇ g of RNA.
  • the gel can be blotted on a nitro-cellulose filter (HybondN+, Amersham) and hybridised with a CYCD4 probe.
  • transgenic plants can be put on Vz MS medium with 1% sucrose, both with and without dexamethasone.
  • a control SR1 seeds should be included.
  • dexamethasone the growth behaviour of the transgenic plants as compared to the control plants is expected to be modified. For example, these transgenic plants may grow faster and/or have additional cells. Furthermore, said plant may be less sensitive to environmental stress compared to the corresponding wild type plant.
  • the invention also relates to a transgenic plant cell which contains (preferably stably integrated into the genome) a nucleic acid molec ⁇ le according to the invention or part thereof, wherein the transcription and/or expression of the nucleic 27 acid molecule or part thereof leads to reduction of the synthesis of a cell cycle interacting protein.
  • the reduction is achieved by an anti-sense, sense, ribozyme, co-suppression and/or dominant mutant effect.
  • Antisense and “antisense nucleotides” means DNA or RNA constructs which block the expression of the naturally occurring gene product.
  • nucleic acid molecules according to the invention opens up the possibility to produce transgenic plant cells with a reduced level of the protein as described above and, thus, with a defect in cell division.
  • Techniques how to achieve this are well known to the person skilled in the art. These include, for example, the expression of antisense-RNA, ribozymes, of molecules which combine antisense and ribozyme functions and/or of molecules which provide for a co-suppression effect; see also supra.
  • the nucleic acid molecule encoding the antisense-RNA is preferably of homologous origin with respect to the plant species used for transformation.
  • nucleic acid molecules which display a high degree of homology to endogenously occurring nucleic acid molecules encoding a mitogenic cyciin.
  • the homology is preferably higher than 80%, particularly higher than 90% and still more preferably higher than 95%.
  • the present invention also relates to transgenic plants comprising the above- described transgenic plant cells. These may show, for example, a deficiency in cell division and/or reduced growth characteristics compared to wild type plants.
  • the present invention also relates to cultured plant tissues comprising transgenic plant cells as described above which either show overexpression of a protein according to the invention or a reduction in synthesis of such a protein.
  • Any transformed plant obtained according to the invention can be used in a conventional breeding scheme or in in vitro plant propagation to produce more transformed plants with the same characteristics and/or can be used to introduce the same characteristic in other varieties of the same or related species. Such plants are also part of the invention. Seeds obtained from the transformed plants genetically also contain the same characteristic and are part of the invention.
  • the present invention is in principle applicable to any plant and crop that can be transformed with any of the transformation method known to those skilled in the art and includes for instance corn, wheat, barley, rice, oilseed crops, cotton, tree species, sugar beet, cassava, tomato, potato, numerous other vegetables, fruits.
  • the invention also relates to harvestable parts and to propagation material of the transgenic plants according to the invention which either contain transgenic plant cells expressing a nucleic acid molecule according to the invention or which contain cells which show a reduced level of the described protein.
  • Harvestable parts can be in principle any useful parts of a plant, for example, flowers, pollen, seedlings, tubers, leaves, stems, fruit, seeds, roots etc.
  • Propagation material includes, for example, seeds, fruits, cuttings, seedlings, tubers, rootstocks etc.
  • the present invention further relates to a method for identifying and obtaining an activator or inhibitor of mitogenic cyclins comprising the steps of:
  • read out system in context with the present invention means a DNA sequence which upon transcription and/or expression in a cell, tissue or organism provides for a scorable and/or selectable phenotype.
  • read out systems are well known to those skilled in the art and comprise, for example, recombinant DNA molecules and marker genes as described above and in the appended example.
  • plurality of compounds in a method of the invention is to be understood as a plurality of substances which may or may not be identical.
  • Said compound or plurality of compounds may be chemically synthesized or microbiologically produced and/or comprised in, for example, samples, e.g., cell extracts from, e.g., plants, animals or microorganisms.
  • said compound(s) may be known in the art but hitherto not known to be capable of suppressing or activating mitogenic cyclins.
  • the reaction mixture may be a cell free extract or may comprise a cell or tissue culture. Suitable set ups for the method of the invention are known to the person skilled in the art and are, for example, generally described in Alberts et al., Molecular Biology of the Cell, third edition
  • the plurality of compounds may be, e.g., added to the reaction mixture, culture medium, injected into the cell or sprayed onto the plant.
  • a sample containing a compound or a plurality of compounds is identified in the method of the invention, then it is either possible to isolate the compound from the original sample identified as containing the compound capable of suppressing or activating mitogenic cyclins, or one can further subdivide the original sample, for example, if it consists of a plurality of different compounds, so as to reduce the number of different substances per sample and repeat the method with the subdivisions of the original sample.
  • the steps described above can be performed several times, preferably until the sample identified according to the method of the invention only comprises a limited number of or only one substance(s).
  • said sample comprises substances of similar chemical and/or physical properties, and most preferably said substances are identical.
  • the compound identified according to the above described -> method or its derivative is further formulated in a form suitable for the application in plant breeding or plant cell and tissue culture.
  • the compounds which can be tested and identified according to a method of the invention may be expression libraries, e.g., cDNA expression libraries, peptides, proteins, nucleic acids, antibodies, small organic compounds, hormones, peptidomimetics, PNAs or the like (Milner, Nature Medicine 1 (1995), 879-880;
  • genes encoding a putative regulator of mitogenic cyciin and/or which excert their effects up- or downstream the mitogenic cyciin of the invention may be identified using, for example, insertion mutagenesis using, for example, gene targeting vectors known in the art (see, e.g., Hayashi, Science 258 (1992),
  • Said compounds can also be functional derivatives or analogues of known inhibitors or activators.
  • Methods for the preparation of chemical derivatives and analogues are well known to those skilled in the art and are described in, for example, Beilstein, Handbook of Organic Chemistry, Springer edition New York Inc.,
  • the cell or tissue that may be employed in the method of the invention preferably is a host cell, plant cell or plant tissue of the invention described in the embodiments hereinbefore.
  • Determining whether a compound is capable of suppressing or activating mitogenic cyclins can be done, for example, by monitoring DNA duplication and cell division. It can further be done by monitoring the phenotypic characteristics of the cell of the invention contacted with the compounds and compare it to that of wild-type plants. In an additional embodiment, said characteristics may be compared to that of a cel contacted with a compound which is either known to be capable or incapable of suppressing or activating mitogenic cyclins.
  • the inhibitor or activator identified by the above-described method may prove useful as a herbicide, pesticide and/or as a plant growth regulator.
  • the invention relates to a compound obtained or identified according to the method of the invention said compound being an activator of mitogenic cyclins or an inhibitor of mitogenic cyclins.
  • Such useful compounds can be for example transacting factors which bind to the mitogenic cyciin of the invention. Identification of transacting factors can be carried out using standard methods in the art (see, e.g., Sambrook, supra, and Ausubel, supra). To determine whether a protein binds to the protein of the invention, standard native gel-shift analyses can be carried out. In order to identify a transacting factor which binds to the protein of the invention, the protein of the invention can be used as an affinity reagent in standard protein purification methods, or as a probe for screening an expression library.
  • the transacting factor modulation of its binding to the mitogenic cyciin of the invention can be pursued, beginning with, for example, screening for inhibitors against the binding of the transacting factor to the protein of the present invention.
  • Activation or repression of mitogenic cyclins could then be achieved in plants by applying of the transacting factor (or its inhibitor) or the gene encoding it, e.g. in a vector for transgenic plants.
  • the active form of the transacting factor is a dimer, dominant-negative mutants of the transacting factor could be made in order to inhibit its activity.
  • further components in the pathway leading to activation e.g. signal transduction
  • repression of a gene involved in the control of cell cycle then can be identified. Modulation of the activities of these components can then be pursued, in order to develop additional drugs and methods for modulating the cell cycle in animals and plants.
  • the invention also relates to a diagnostic composition
  • a diagnostic composition comprising at least one of the aforementioned nucleic acid molecules, vectors, proteins, antibodies or compounds and optionally suitable means for detection.
  • Said diagnostic compositions may be used for methods for detecting expression of mitogenic cyclins by detecting the presence of the corresponding mRNA which comprises isolation of mRNA from a cell and contacting the mRNA so obtained with a probe comprising a nucleic acid probe as described above under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of the protein in the cell.
  • Further methods of detecting the presence of a protein according to the present invention comprises immunotechniques well known in the art, for example enzyme linked immunosorbent assay.
  • proteins according to the invention from other organisms such as yeast and animals to influence cell division progression in those other organisms such as mammals or insects.
  • one or more DNA sequences, vectors or proteins of the invention or the above-described antibody or compound are, for instance, used to specifically interfere in the disruption of the expression levels of genes involved in G1/S transition in the cell cycle process in transformed plants, particularly :
  • DNA sequences, vectors or proteins of the invention or the above-described antibody or compound can be used to modulate, for instance, the total architecture, growth and sensitivity to the environment of the plant concerned can be manipulated by the regulation of the expression of the cyciin gene according to the invention.
  • the present invention also relates to the use of a DNA sequence, vector, protein, antibody or compound of the invention for modulating, plant cell cycle, plant cell division and/or growth, for influencing the activity of cyclin- dependent protein kinase in a plant cell, for disrupting plant cell division by influencing the presence or absence or by interfering in the expression of mitogenic cyciin for influencing cell division progression in a host as defined above or for use in a screening method for the identification of inhibitors or activators of cell cycle proteins.
  • nucleic acid molecules according to the invention may also be used for several other applications, for example, for the identification of nucleic acid molecules which encode proteins which interact with the mitogenic cyclins described above. This can be achieved by assays well known in the art such as those described above and also included, for example, as described in
  • a peptide encoded by one of the cDNAs is able to interact with the fusion peptide comprising a peptide of a protein of the invention, the complex is able to direct expression of the reporter gene.
  • the nucleic acid molecules according to the invention and the encoded peptide can be used to identify peptides and proteins interacting with mitogenic cyclins. It is apparent to the person skilled in the art that this and similar systems may then further be exploited for the identification of inhibitors of the binding of the interacting proteins.
  • Figure 1 Sequence alignment of the A. thaliana D-type cyclins.
  • the CYCD4;1 -coding region is aligned with CYCD1 ;1 , CYCD2;1 , CYCD3;1 (GenBank accession numbers X83369; X83370; and X83371 , respectively). Alignment was obtained by the use of the PILEUP program (Genetic Computer Group, Madison, Wl). Black regions indicate positions at which more than half of the sequences are identical. Shaded residues represent conserved substitutions. To obtain maximal similarity, gaps were introduced, represented by dots.
  • Example 1 Identification of a cell cycle interacting protein
  • CDC2aAt-interacting proteins To identify CDC2aAt-interacting proteins a two-hybrid system was used based upon GAL4 recognition sites to regulate the expression of both his3 and lacZ reporter genes.
  • the pGBTCDC2A vector, containing a fusion protein between the C-terminus of the GAL4 DNA-binding domain and CDC2aAt was constructed by cloning the full- lenght coding region of CDC2aAt into the pGBT9 vector.
  • cDNA fusion library was used, constructed from mRNA of Arabidopsis thaliana cell suspensions harvested at various growing stages: early exponential, exponential, early stationary, and stationary phase.
  • the pGBTCDC2A plasmid was cotransformed with the library into the HF7c reporter strain. Approximately 1.2 10 7 independent transformants were screened for their ability to grow on histidine-free medium. A 3-day incubation at 30°C yielded about 1200 colonies. These colonies were tested for their growth on medium without histidine in the presence of 10 mM 3-amino-1 ,2,4-triazole, reducing the number of positives to 250. Next these colonies were tested for the activation of the lacZ gene, and 153 turned out to be both His + and LacZ + . DNA was prepared from the positive clones and sequenced. One of the clones contained a gene (LDV59) encoding a novel mitogenic cyciin.
  • the LDV59 encoded protein also contains the Rb interacting motif.
  • the specificity of the interaction between the LDV59 encoded protein with CDC2aAt was verified by the retransformation of yeast with pGBTCDC2A and pGADLDV59.
  • pGBTCDC2A was cotransformed with a vector containing only the GAL4 activation domain (pGAD424); and pGADLDV59 was cotransformed with a plasmid containing only the GAL4 DNA-binding domain (pGBT9).
  • Transformants were plated, on medium with or without histidine. Only transformants containing both pGBTCDC2A and pGADLDV59 were able to grow in the absence of histidine.
  • Example 2 The LDV59 encoded protein associates with both Cdc2aAt and
  • the pGBTCDC2B vector encoding a fusion protein between the C-terminus of the GAL4 DNA-binding domain and CDC2bAt was constructed by cloning the full-lenght coding region of CDC2bAt into the pGBT9 vector.
  • pGBTCDC2B was transformed with pGADLDV59 in the HF7c yeast and cotransformants were plated on medium with or without histidine.
  • pGBTCDC2B was cotransformed with a vector containing only the GAL4 activation domain (pGAD424); and pGADLDV59 was cotransformed with a plasmid containing only the GAL4 DNA-binding domain (pGBT9).
  • Arabidopsis cell suspensions ecotype Col.-O maintained as described by Glab et al. (FEBS Lett. 353 (1994), pag. 207-211 ) were depleted for growth factors for 48 hrs. by resuspending them in medium lacking auxin (2,4-D), cytokinin (BAP), and sucrose. After 48 hrs. the cells were split into eight aliquots, which were resuspended in medium containing sucrose or lacking sucrose, containing auxin or lacking auxin, and containing cytokinin or lacking cytokinin. After 6 hrs. cultivation RNA was extracted from the cells. An RNA gel blot was probed with the LDV59 gene. A hybridization signal was only observed for the cells supplemented with cytokinin and sucrose, indication that the LDV59 gene is specially induced by these mitogenic agents.
  • Example 5 LDV 59 expression
  • Plant material was fixed in 2.5% glutaraidehyde in 0.1 M cacodylate buffer (pH7.2). Fixed tissue was dehydrated with ethanol, cleared with toluene, and embedded in paraffin. Embedded tissue was sliced into serial 10 ⁇ m sections and attached to coated microscope slides. 35 S-UTP-labeled sense and antisense RNA of a cDNA LDV59 subcloned in PGem2 were generated by run-off transcription using T7 and Sp6 RNA polymerases according to the manufacturer's instructions (Boehringer Mannheim). Full-length transcripts were reduced to an average length of 0.3kb by alkaline hydrolysis (Cox et al., 1984, Dev.Biol.,101 , p.485).
  • RNA in situ hybridization was carried out essentially as described by Angerer and Angerer (1992) in "In situ hybridization”: A practical approach (The Practical Approach series, Wilkinson DG,ed,Oxford Press, pp.15-32). Stringent wash was performed in 0.1 SSC (1X SSC; 150mM NaCI, 15mM Na3-citrate, pH7.0) at 62°C for 60 min to avoid cross hybridization.
  • pericycle cells neighbouring one protoxylem pole show an intense hybridization signal. As lateral roots expand very strong signal is mainly observed at its basis. At that stage a weak or no signal is detected in the meristematic cells of the lateral root tip. At later stages of root development, only a subset or group of cells in the root meristem show high accumulation of LDV59 mRNA. Mature root meristems barely show any expression of the LDV59 gene. Cell files in specific regions along the vascular tissue show a weak and uniform expression pattern. Similar cell files of the vascular tissue show a completely different pattern of expression. Alternating stretches of cells along the vascular 1 cylinder expressing and not expressing the LDV59 are observed.
  • tissue sections along the vascular tissue contained only one single cell expressing the LDV59 gene.
  • LDv59 expression was observed along the vascular tissue from the filament and young ovaries.
  • high accumulation of LDV59 mRNA was observed in the fertilized ovule, most likely in the megaspore- mother-cell burried in the nucellus tissue.
  • embryo development expression was high in globular and heart stages embryos and low in mature embryo.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pest Control & Pesticides (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'invention concerne des séquences d'ADN codant pour des cyclines mitogènes et des procédés de leur fabrication. L'invention concerne également des vecteurs comprenant ces séquences d'ADN, lesdites séquences étant liées de manière fonctionnelle à des éléments régulateurs permettant l'expression dans des cellules hôtes procaryotes et/ou eucaryotes. De plus, l'invention se rapporte à des protéines codées par ces séquences d'ADN, des anticorps à ces protéines et des procédés de leur fabrication. En outre, l'invention concerne des compositions diagnostiques comprenant les séquences d'ADN, les vecteurs, les protéines et les anticorps susmentionnés. L'invention se rapporte aussi à des procédés d'identification de composés capables d'activer d'inhiber le cycle cellulaire. Enfin, elle se rapporte à des cellules de plantes transgéniques, à des tissus végétaux et à des plantes comprenant les séquences d'ADN et vecteurs susmentionnés ainsi qu'à l'utilisation desdites séquences d'ADN, des vecteurs, des protéines, des anticorps et / ou des composés identifiés par le procédé de cette invention dans des cellules végétales et des cultures de tissus aussi bien qu'en sélection végétale et/ou en agriculture.
PCT/EP1998/006749 1997-10-24 1998-10-23 Nouveau cycline mitogene et son utilisation WO1999022002A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000518093A JP2001520887A (ja) 1997-10-24 1998-10-23 新規な分裂促進性サイクリンおよびその使用
AU15572/99A AU754851B2 (en) 1997-10-24 1998-10-23 A novel mitogenic cyclin and uses thereof
CA002307171A CA2307171A1 (fr) 1997-10-24 1998-10-23 Nouveau cycline mitogene et son utilisation
EP98959796A EP1025232A1 (fr) 1997-10-24 1998-10-23 Nouveau cycline mitogene et son utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203303.9 1997-10-24
EP97203303 1997-10-24

Publications (1)

Publication Number Publication Date
WO1999022002A1 true WO1999022002A1 (fr) 1999-05-06

Family

ID=8228857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/006749 WO1999022002A1 (fr) 1997-10-24 1998-10-23 Nouveau cycline mitogene et son utilisation

Country Status (5)

Country Link
EP (1) EP1025232A1 (fr)
JP (1) JP2001520887A (fr)
AU (1) AU754851B2 (fr)
CA (1) CA2307171A1 (fr)
WO (1) WO1999022002A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054489A1 (fr) * 1998-04-21 1999-10-28 Cropdesign N.V. Vegetaux tolerants aux agressions
WO2000017364A2 (fr) * 1998-09-23 2000-03-30 Pioneer Hi-Bred International, Inc. Polynucleotides et polypeptides de cycline d et leurs utilisations
WO2001020020A2 (fr) * 1999-09-10 2001-03-22 Cropdesign N.V. Procede d'identification de composes presentant un effet herbicide ou regulateur de la croissance sur des plantes
WO2001023594A2 (fr) * 1999-09-27 2001-04-05 Pioneer Hi-Bred International, Inc. Amelioration de la tolerance au stress dans le mais par manipulation des genes de regulation du cycle cellulaire
WO2001085946A3 (fr) * 2000-05-12 2003-03-13 Cropdesign Nv Molecules d'acide nucleique codant pour des proteines de cycle cellulaire de plantes et leurs utilisations
US7371927B2 (en) 2003-07-28 2008-05-13 Arborgen, Llc Methods for modulating plant growth and biomass
AU2007201513B2 (en) * 2000-05-12 2011-06-23 Cropdesign N.V. Nucleic acid molecules encoding plant cell cycle proteins and uses therefor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009685A1 (fr) * 1990-11-29 1992-06-11 The Australian National University Procede de regulation de la proliferation et de la croissance des cellules vegetales
WO1993015213A1 (fr) * 1992-01-24 1993-08-05 Zeneca Limited Regulation de la transcription d'un gene
WO1993024514A1 (fr) * 1992-05-26 1993-12-09 Mitotix Cycline de type d et utilisations correspondantes
WO1997016447A1 (fr) * 1995-10-31 1997-05-09 Mitotix, Inc. Inhibiteurs de kinases cyclinodependantes
WO1997020842A1 (fr) * 1995-12-01 1997-06-12 Centre National De La Recherche Scientifique (C.N.R.S.) Nouveaux derives de purine possedant notamment des proprietes anti-proliferatives et leurs applications biologiques
WO1998003631A1 (fr) * 1996-07-18 1998-01-29 The Salk Institute For Biological Studies Procede d'accroissement de la croissance et du rendement de plantes
WO1998042851A1 (fr) * 1997-03-26 1998-10-01 Cambridge University Technical Services Ltd. Plantes presentant une croissance modifiee

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009685A1 (fr) * 1990-11-29 1992-06-11 The Australian National University Procede de regulation de la proliferation et de la croissance des cellules vegetales
WO1993015213A1 (fr) * 1992-01-24 1993-08-05 Zeneca Limited Regulation de la transcription d'un gene
WO1993024514A1 (fr) * 1992-05-26 1993-12-09 Mitotix Cycline de type d et utilisations correspondantes
WO1997016447A1 (fr) * 1995-10-31 1997-05-09 Mitotix, Inc. Inhibiteurs de kinases cyclinodependantes
WO1997020842A1 (fr) * 1995-12-01 1997-06-12 Centre National De La Recherche Scientifique (C.N.R.S.) Nouveaux derives de purine possedant notamment des proprietes anti-proliferatives et leurs applications biologiques
WO1998003631A1 (fr) * 1996-07-18 1998-01-29 The Salk Institute For Biological Studies Procede d'accroissement de la croissance et du rendement de plantes
WO1998042851A1 (fr) * 1997-03-26 1998-10-01 Cambridge University Technical Services Ltd. Plantes presentant une croissance modifiee

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
DAHL M ET AL: "THE D-TYPE ALFALFA CYCLIN GENE CYCMS4 COMPLEMENTS G1 CYCLIN-DEFICIENT YEAST AND IS INDUCED IN THE G1 PHASE OF THE CELL CYCLE", PLANT CELL, vol. 7, November 1995 (1995-11-01), pages 1847 - 1857, XP002045513 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; CRUZ-GARCIA, F., ET AL.: "Effect of stimulating maize germination on cell cycle proteins", XP002095095 *
DE VEYLDER, L., ET AL.: "Identification of proteins interacting with the Arabidopsis Cdc2at protein", J. EXPERIMENTAL BOTANY, vol. 48, no. 317, December 1997 (1997-12-01), pages 2113 - 2114, XP002067456 *
DOERNER P ET AL: "CONTROL OF ROOT GROWTH AND DEVELOPMENT BY CYCLIN EXPRESSION", NATURE, vol. 380, 11 April 1996 (1996-04-11), pages 520 - 523, XP002045509 *
DOONAN J: "PLANT GROWTH: ROOTS IN THE CELL CYCLE", CURRENT BIOLOGY, vol. 6, no. 7, 1 July 1996 (1996-07-01), pages 788/789, XP002045511 *
GRAFI G ET AL: "A MAIZE CDNA ENCODING A MEMBER OF THE RETINOBLASTOMA PROTEIN FAMILY: INVOLVEMENT IN ENDOREDUPLICATION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, no. 17, 20 August 1996 (1996-08-20), pages 8962 - 8967, XP002042542 *
HEMERLY A ET AL: "DOMINANT NEGATIVE MUTANTS OF THE CDC2 KINASE UNCOUPLE CELL DIVISION FROM ITERATIVE PLANT DEVELOPMENT", EMBO JOURNAL, vol. 14, no. 16, 1995, pages 3925 - 3936, XP002045514 *
NAKAMURA, Y.: "Arabidopis thaliana genomic DNA, chromosome 5, P1 clone: MNA5", EMBL ACCESSION NO. AB011479, 10 March 1998 (1998-03-10), XP002094910 *
PHYSIOLOGIA PLANTARUM, vol. 102, no. 4, April 1998 (1998-04-01), pages 573 - 581 *
PLANCHAIS, S., ET AL.: "Roscovitine, a novel cyclin-dependent kinase inhibitor, characterizes restriction point and G2/M transition in tobacco BY-2 cell suspension", PLANT JOURNAL, vol. 12, no. 1, 1997, pages 191 - 202, XP002094755 *
SONI R ET AL: "A FAMILY OF CYCLIN D HOMOLOGS FROM PLANTS DIFFERENTIALLY CONTROLLED BY GROWTH REGULATORS AND CONTAINING THE CONSERVED RETINOBLASTOMA PROTEIN INTERACTION MOTIF", PLANT CELL, vol. 7, January 1995 (1995-01-01), pages 85 - 103, XP002045510 *
VEYLDER DE L ET AL: "THE ARABIDOPSIS CKS1 AT PROTEIN BINDS THE CYCLIN-DEPENDENT KINASES CDC2AAT AND CDC2BAT", FEBS LETTERS, vol. 412, no. 3, 4 August 1997 (1997-08-04), pages 446 - 452, XP002047992 *
WANG H ET AL: "A PLANT CYCLIN-DEPENDENT KINASE INHIBITOR GENE", NATURE, vol. 386, 3 April 1997 (1997-04-03), pages 451/452, XP002054969 *
WANG, H., ET AL.: "ICK1, a cyclin-dependent protein kinase inhibitor from Arabidopsis thaliana interacts with both Cdc2a and CycD3, and its expression is induced by abscisic acid", THE PLANT JOURNAL, vol. 15, no. 4, August 1998 (1998-08-01), pages 501 - 510, XP002095094 *
XI Q ET AL: "PLANT CELLS CONTAIN A NOVEL MEMBER OF THE RETINOBLASTOMA FAMILY OF GROWTH REGULATORY PROTEINS", EMBO JOURNAL, vol. 15, no. 18, 1996, pages 4900 - 4908, XP002045512 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054489A1 (fr) * 1998-04-21 1999-10-28 Cropdesign N.V. Vegetaux tolerants aux agressions
US7799566B2 (en) 1998-09-23 2010-09-21 Pioneer Hi-Bred International, Inc. Cyclin D polynucleotides, polypeptides and uses thereof
WO2000017364A2 (fr) * 1998-09-23 2000-03-30 Pioneer Hi-Bred International, Inc. Polynucleotides et polypeptides de cycline d et leurs utilisations
WO2000017364A3 (fr) * 1998-09-23 2000-07-13 Pioneer Hi Bred Int Polynucleotides et polypeptides de cycline d et leurs utilisations
US6518487B1 (en) 1998-09-23 2003-02-11 Pioneer Hi-Bred International, Inc. Cyclin D polynucleotides, polypeptides and uses thereof
WO2001020020A2 (fr) * 1999-09-10 2001-03-22 Cropdesign N.V. Procede d'identification de composes presentant un effet herbicide ou regulateur de la croissance sur des plantes
WO2001020020A3 (fr) * 1999-09-10 2001-09-27 Cropdesign Nv Procede d'identification de composes presentant un effet herbicide ou regulateur de la croissance sur des plantes
WO2001023594A2 (fr) * 1999-09-27 2001-04-05 Pioneer Hi-Bred International, Inc. Amelioration de la tolerance au stress dans le mais par manipulation des genes de regulation du cycle cellulaire
WO2001023594A3 (fr) * 1999-09-27 2001-12-06 Pioneer Hi Bred Int Amelioration de la tolerance au stress dans le mais par manipulation des genes de regulation du cycle cellulaire
WO2001085946A3 (fr) * 2000-05-12 2003-03-13 Cropdesign Nv Molecules d'acide nucleique codant pour des proteines de cycle cellulaire de plantes et leurs utilisations
AU2001270936B2 (en) * 2000-05-12 2007-01-11 Cropdesign N.V. Nucleic acid molecules encoding plant cell cycle proteins and uses therefor
AU2007201513B2 (en) * 2000-05-12 2011-06-23 Cropdesign N.V. Nucleic acid molecules encoding plant cell cycle proteins and uses therefor
AU2007201513A8 (en) * 2000-05-12 2011-07-14 Cropdesign N.V. Nucleic acid molecules encoding plant cell cycle proteins and uses therefor
AU2007201513B8 (en) * 2000-05-12 2011-07-14 Cropdesign N.V. Nucleic acid molecules encoding plant cell cycle proteins and uses therefor
US8193414B2 (en) * 2000-05-12 2012-06-05 Cropdesign N.V. Method for modulating plant growth, nucleic acid molecules and polypeptides encoded thereof useful as modulating agent
AU2001270936C1 (en) * 2000-05-12 2014-01-16 Cropdesign N.V. Nucleic acid molecules encoding plant cell cycle proteins and uses therefor
AU2007201513C1 (en) * 2000-05-12 2014-01-16 Cropdesign N.V. Nucleic acid molecules encoding plant cell cycle proteins and uses therefor
US7371927B2 (en) 2003-07-28 2008-05-13 Arborgen, Llc Methods for modulating plant growth and biomass

Also Published As

Publication number Publication date
EP1025232A1 (fr) 2000-08-09
AU754851B2 (en) 2002-11-28
CA2307171A1 (fr) 1999-05-06
AU1557299A (en) 1999-05-17
JP2001520887A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
AU754803B2 (en) Cyclin-dependent kinase inhibitors and uses thereof
JP2002541763A (ja) 植物中のエチレン応答因子１（ｅｒｆ１）
CA2459079C (fr) Gene de resistance derive de plantes
US20150159166A1 (en) Plant drought tolerance and nitrogen use efficiency by reducing plant sensitivity to ethylene
CA2284136C (fr) Procede et moyens de modulation des proteines du cycle cellulaire des plantes et utilisation de ces moyens pour controler la croissance cellulaire des plantes
US10982218B2 (en) Strong activation domain
JP2006512071A (ja) ストレス耐性を与えるイネの新規遺伝子ｏｓｉｓａｐ１及びストレス耐性を与える方法
US7119251B2 (en) Basal endosperm transfer cell layer (BELT) specific genes
EP1163341A2 (fr) Procede pour accelerer et/ou ameliorer la croissance et/ou le rendement de vegetaux ou pour modifier leur architecture
JP2003532421A (ja) 植物の細胞周期タンパク質をコードする核酸分子およびその使用
CA2620766C (fr) Facteur de transcription induit par le stress derive du mais
AU754851B2 (en) A novel mitogenic cyclin and uses thereof
AU754804B2 (en) Method and means for modulating plant cell cycle proteins and their use in controlling plant cell growth
US6710227B1 (en) Cyclin-dependent kinase inhibitors and uses thereof
WO2000037488A2 (fr) Nouveaux genes a boite mads et utilisation de ces genes
AU776605B2 (en) Novel cell cycle genes and uses thereof
AU2003200717B2 (en) Cyclin-dependent kinase inhibitors and uses thereof
AU2007201818A1 (en) Cyclin-dependent kinase inhibitors and uses thereof
MXPA00001449A (en) Genetic control of plant growth and development

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 15572/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2307171

Country of ref document: CA

Ref country code: CA

Ref document number: 2307171

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998959796

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09530209

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998959796

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 15572/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998959796

Country of ref document: EP